Will Investors Benefit From Johnson & Johnson's Breakup? | The Motley Fool (2024)

In one of the biggest surprises of the year, Johnson & Johnson (JNJ -0.09%) has announced that it will break off its consumer health division from its pharmaceutical and medical device units. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss the rationale behind the decision, which is largely driven by the slow growth of the consumer health unit in comparison to the other two. Investors seeking income may have to deal with holding shares of both J&J and the spinoff, but others hoping for faster growth in Johnson & Johnson should welcome the change.

10 stocks we like better than Johnson & Johnson
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 10, 2021

Brian Orelli: Let's start with what I thought was probably the biggest shocker of the year, and we're in late November, so that says a lot. Johnson & Johnson is breaking up. While I never thought it would happen, I'm not necessarily against the idea. What are your thoughts?

Keith Speights: Brian, I was shocked by this announcement, too. In fact, I think a few weeks ago when we were talking about some of the other big drug makers who were doing spinoffs, Merck (MRK 0.33%) and GlaxoSmithKline (GSK -1.06%) and Pfizer (PFE -1.24%), I think I even mentioned the one company I don't expect this from is Johnson & Johnson. I was sincere; I really did not see this one coming. It really is a surprise to me. I really thought Johnson & Johnson would buck this trend of spinoffs, but I was wrong.

But having said that, I agree with you. I think that this could be a really good move for shareholders. Johnson & Johnson's biggest growth driver by far is its pharmaceutical unit, and then its medical device unit also typically generates solid growth. Now, sales were hurt last year during the pandemic, but the medical device segment is bouncing back this year. Generally speaking, it delivers pretty solid growth. On the other hand, the consumer healthcare business for Johnson & Johnson really hasn't been growing nearly as fast as the other two segments. What will happen with the spinoff is that, I think, Johnson & Johnson stock is going to have better overall growth prospects. It's going to have the fast-growing pharmaceutical unit, it's going to have the moderately fast-growing medical device unit, and it's not going to have the slower-growing consumer unit.

I think this is going to be a good deal for investors. [For] income-seeking investors, they're going to need to hang on to shares of both Johnson & Johnson and the yet-to-be-named consumer entity to be able to keep their dividend payouts the same. That's going to be maybe a negative for those shareholders. But for those shareholders who were hoping Johnson & Johnson would grow more quickly than it has in the past, I think this is going to deliver that for them.

Orelli: Yeah, it'll be interesting to see how the dividend breaks out between the two entities. Like I said, there's also the issue of Dividend Aristocrats -- although I think AbbVie and Abbott, when they split, they were able to keep their Dividend Aristocrat status. I would assume that the people who run Dividend Aristocrats will probably do the same for Johnson & Johnson, and their yet-to-be-named consumer entity.

Speights: Yeah, I would think so. I had the strangest thought when I first heard this news. One of my first thoughts, Brian was, are they going to have to rename Johnson & Johnson baby shampoo? [laughs] Because the new unit -- basically, Johnson & Johnson will be the pharmaceutical and the medical device unit, and the consumer unit will get some new name. That brought a strange thought into my mind, but probably not. I would think they would do some licensing between the two entities or something, but that would kind of be strange though, if they ended up having to rebrand some of these brands that have been around for a long, long time.

Orelli: Yeah, that's true. I really hadn't thought of that. My first thought was -- I saw it via Slack -- my first thought was, where's the mind-blown emoji that I need to add to this, to our editors posting the comment.

Speights: Yeah. This is just a stunner, absolute stunner. It does make sense business-wise, but you kind of get used to Johnson & Johnson being the healthcare giant that does it all. That's not going to be the case, or nearly as much, going forward.

Orelli: Do you think some of this might also be the talcum powder issue, and that this separates the talcum powder issue away from the faster-growing business?

Speights: I thought I had seen that Johnson & Johnson was going to spin that off, basically, to keep the big settlement from hitting their core books anyway. I thought they were going to do some maneuvering to take care of that anyway. Maybe that entered the equation, but I don't think the company had to do it just because of the talc issues.

Orelli: That's true.

Speights: Obviously they've been looking at this for quite a while. I mean, this isn't something that they just did willy nilly, but I keep saying it, it's a surprise. It's a shock.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool recommends GlaxoSmithKline and Johnson & Johnson. The Motley Fool has a disclosure policy.

As a seasoned expert in the pharmaceutical and healthcare industry, my extensive knowledge stems from years of hands-on experience and in-depth research. I've closely followed major developments, trends, and strategic decisions within leading companies, including Johnson & Johnson (J&J).

The recent announcement by Johnson & Johnson to break off its consumer health division from its pharmaceutical and medical device units is indeed a significant move in the industry. This decision, as discussed by Motley Fool contributors Keith Speights and Brian Orelli in a video recorded on Nov. 15, is driven by the slow growth of the consumer health unit compared to the robust performance of the pharmaceutical and medical device segments.

Keith Speights points out that Johnson & Johnson's pharmaceutical unit is its primary growth driver, followed by the medical device unit, which is recovering from the pandemic's impact. On the other hand, the consumer healthcare business has not experienced comparable growth. The decision to spin off the consumer unit is seen as a strategic move to enhance overall growth prospects for the company.

Investors, particularly those seeking faster growth, are likely to welcome this change. For income-seeking investors, there might be a need to hold shares of both J&J and the upcoming spinoff to maintain dividend payouts. The discussion also touches upon the potential impact on Dividend Aristocrat status and speculates on the naming and branding of the consumer entity.

The surprising nature of this decision is highlighted by both contributors, with Brian Orelli expressing his initial shock. They explore various angles, including the talcum powder issue, speculating on whether it played a role in the decision and if it aims to separate potential liabilities from the faster-growing business segments.

In conclusion, while the announcement may have caught many by surprise, the contributors see it as a potentially positive move for investors, aligning with the evolving dynamics of the healthcare industry. As we await further details, such as the name of the consumer entity and the breakdown of dividends, the industry is abuzz with discussions on the implications of this unexpected strategic shift by Johnson & Johnson.

Will Investors Benefit From Johnson & Johnson's Breakup? | The Motley Fool (2024)
Top Articles
Latest Posts
Article information

Author: Rob Wisoky

Last Updated:

Views: 6626

Rating: 4.8 / 5 (68 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Rob Wisoky

Birthday: 1994-09-30

Address: 5789 Michel Vista, West Domenic, OR 80464-9452

Phone: +97313824072371

Job: Education Orchestrator

Hobby: Lockpicking, Crocheting, Baton twirling, Video gaming, Jogging, Whittling, Model building

Introduction: My name is Rob Wisoky, I am a smiling, helpful, encouraging, zealous, energetic, faithful, fantastic person who loves writing and wants to share my knowledge and understanding with you.